CADTH Canadian Drug Expert Committee recommendation : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, a tNF[alpha] antagonist. Vedolizumab (Entyvio -- Takeda Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

CADTH common drug review.

CADTH Common Drug Review

Language:

English

Subjects (All):

Outcome assessment (Medical care).

Physical Description:

1 online resource.

Edition:

First edition.

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2020.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that vedolizumab subcutaneous (SC) be reimbursed for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or infliximab, a tumour necrosis factor alpha (TNFα) antagonist, only if the following conditions are met.

Notes:

Description based on publisher supplied metadata and other sources.